



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

31st March, 2026

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a Final Order from the TDS Authority, INT Tax Circle 2(3)(2) with the TDS Demand Liability of Rs 2.01 Crores. The relevant details to be disclosed is as under:

| Sr no | Particulars | Details |
|-------|---|---|
| 1 | Name of the authority | TDS Authority – INT Tax Circle 2(3)(2) |
| 2 | Nature and details of the action(s) taken, initiated or order(s) passed | Demand Liability issued under TDS default u/s 201 of Rs INR 2.01 Crore (TDS Rs 1.11 Cr + Interest 0.90 Cr) for the AY: 2020-2021. |
| 3 | Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority. | Assessment Order u/s 201(1)/ 201(1A) dated 31 st March, 2026 |
| 4 | Details of violation(s) / contravention(s) committed or alleged to be committed. | N.A. |
| 5 | Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible | No impact on the financial statements as the Company is contesting the assessment order and is in the process of filing an appeal before the appellate authority. |

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151